Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2444

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 2444
---
,764  
     38,023,784  
     5,845  
     1  
     1,032,125  
     (43,089,821) 
     (42,057,695)
  
    Stock
    based compensation expense 
     -  
     -  
     -  
     -  
     -  
     -  
     4,431  
     -  
     4,431 
  
    Net
    loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (572,211) 
     (572,211)
  
    Balance
    at February 13, 2024 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     5,845  
    $1  
    $1,036,556  
    $(43,662,032) 
    $(42,625,475)

See accompanying notes to the consolidated financial
statements

Reflects a 1-for-100 reverse stock split effective
January 8, 2025

F-5

CERO
THERAPEUTICS HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

    For the  period from  February 14,  2024 through December 31, 2024  
    For the  period from  January 1, 2024 through  February 13, 2024  
    For the year ended  December 31, 2023 

    (Successor)  
    (Predecessor)  
    (Predecessor) 
  
    Cash flows from operating activities: 

    Net loss 
    $(7,732,212) 
    $(572,211) 
    $(7,289,577)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Gain from settlement of liabilities with vendors 
     (3,339,223) 
     -  
     - 
  
    Depreciation expense 
     400,825  
     37,356